Literature DB >> 32016007

Restaging after chemoradiotherapy for locally advanced esophageal cancer.

Ingmar L Defize1,2, Richard van Hillegersberg2, Stella Mook1, Gert J Meijer1, Steven H Lin3, Jelle P Ruurda2, Peter S N van Rossum1.   

Abstract

Entities:  

Year:  2019        PMID： 32016007      PMCID： PMC6976470          DOI： 10.21037/atm.2019.11.57

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  13 in total

1.  Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer.

Authors:  Peter S N van Rossum; Astrid L H M W van Lier; Marco van Vulpen; Onne Reerink; Jan J W Lagendijk; Steven H Lin; Richard van Hillegersberg; Jelle P Ruurda; Gert J Meijer; Irene M Lips
Journal:  Radiother Oncol       Date:  2015-05-19       Impact factor: 6.280

2.  Multimodal Imaging of Pathologic Response to Chemoradiation in Esophageal Cancer.

Authors:  Penny Fang; Benjamin C Musall; Jong Bum Son; Amy C Moreno; Brian P Hobbs; Brett W Carter; Bryan M Fellman; Osama Mawlawi; Jingfei Ma; Steven H Lin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-03-02       Impact factor: 7.038

3.  Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(/CT): a systematic review and meta-analysis.

Authors:  T E Kroese; L Goense; R van Hillegersberg; B de Keizer; S Mook; J P Ruurda; P S N van Rossum
Journal:  Dis Esophagus       Date:  2018-12-01       Impact factor: 3.429

4.  Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.

Authors:  Joel Shapiro; J Jan B van Lanschot; Maarten C C M Hulshof; Pieter van Hagen; Mark I van Berge Henegouwen; Bas P L Wijnhoven; Hanneke W M van Laarhoven; Grard A P Nieuwenhuijzen; Geke A P Hospers; Johannes J Bonenkamp; Miguel A Cuesta; Reinoud J B Blaisse; Olivier R C Busch; Fiebo J W Ten Kate; Geert-Jan M Creemers; Cornelis J A Punt; John Th M Plukker; Henk M W Verheul; Ernst J Spillenaar Bilgen; Herman van Dekken; Maurice J C van der Sangen; Tom Rozema; Katharina Biermann; Jannet C Beukema; Anna H M Piet; Caroline M van Rij; Janny G Reinders; Hugo W Tilanus; Ewout W Steyerberg; Ate van der Gaast
Journal:  Lancet Oncol       Date:  2015-08-05       Impact factor: 41.316

Review 5.  Imaging of oesophageal cancer with FDG-PET/CT and MRI.

Authors:  P S N van Rossum; A L H M W van Lier; I M Lips; G J Meijer; O Reerink; M van Vulpen; M G E H Lam; R van Hillegersberg; J P Ruurda
Journal:  Clin Radiol       Date:  2014-08-27       Impact factor: 2.350

Review 6.  Endoscopic biopsy and EUS for the detection of pathologic complete response after neoadjuvant chemoradiotherapy in esophageal cancer: a systematic review and meta-analysis.

Authors:  Peter S N van Rossum; Lucas Goense; Jihane Meziani; Johannes B Reitsma; Peter D Siersema; Frank P Vleggaar; Marco van Vulpen; Gert J Meijer; Jelle P Ruurda; Richard van Hillegersberg
Journal:  Gastrointest Endosc       Date:  2015-11-26       Impact factor: 9.427

7.  Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.

Authors:  Bo Jan Noordman; Manon C W Spaander; Roelf Valkema; Bas P L Wijnhoven; Mark I van Berge Henegouwen; Joël Shapiro; Katharina Biermann; Ate van der Gaast; Richard van Hillegersberg; Maarten C C M Hulshof; Kausilia K Krishnadath; Sjoerd M Lagarde; Grard A P Nieuwenhuijzen; Liekele E Oostenbrug; Peter D Siersema; Erik J Schoon; Meindert N Sosef; Ewout W Steyerberg; J Jan B van Lanschot
Journal:  Lancet Oncol       Date:  2018-06-01       Impact factor: 41.316

8.  Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial.

Authors:  Bo Jan Noordman; Bas P L Wijnhoven; Sjoerd M Lagarde; Jurjen J Boonstra; Peter Paul L O Coene; Jan Willem T Dekker; Michael Doukas; Ate van der Gaast; Joos Heisterkamp; Ewout A Kouwenhoven; Grard A P Nieuwenhuijzen; Jean-Pierre E N Pierie; Camiel Rosman; Johanna W van Sandick; Maurice J C van der Sangen; Meindert N Sosef; Manon C W Spaander; Roelf Valkema; Edwin S van der Zaag; Ewout W Steyerberg; J Jan B van Lanschot
Journal:  BMC Cancer       Date:  2018-02-06       Impact factor: 4.430

9.  Prognosis and Treatment After Diagnosis of Recurrent Esophageal Carcinoma Following Esophagectomy with Curative Intent.

Authors:  K Parry; E Visser; P S N van Rossum; N Haj Mohammad; J P Ruurda; R van Hillegersberg
Journal:  Ann Surg Oncol       Date:  2015-09-03       Impact factor: 5.344

10.  Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study.

Authors:  A S Borggreve; S Mook; M Verheij; V E M Mul; J J Bergman; A Bartels-Rutten; L C Ter Beek; R G H Beets-Tan; R J Bennink; M I van Berge Henegouwen; L A A Brosens; I L Defize; J M van Dieren; H Dijkstra; R van Hillegersberg; M C Hulshof; H W M van Laarhoven; M G E H Lam; A L H M W van Lier; C T Muijs; W B Nagengast; A J Nederveen; W Noordzij; J T M Plukker; P S N van Rossum; J P Ruurda; J W van Sandick; B L A M Weusten; F E M Voncken; D Yakar; G J Meijer
Journal:  BMC Cancer       Date:  2018-10-20       Impact factor: 4.430
View more
  1 in total

1.  18F-FDG PET/CT Metrics Are Correlated to the Pathological Response in Esophageal Cancer Patients Treated With Induction Chemotherapy Followed by Neoadjuvant Chemo-Radiotherapy.

Authors:  Nicola Simoni; Gabriella Rossi; Giulio Benetti; Michele Zuffante; Renato Micera; Michele Pavarana; Stefania Guariglia; Emanuele Zivelonghi; Valentina Mengardo; Jacopo Weindelmayer; Simone Giacopuzzi; Giovanni de Manzoni; Carlo Cavedon; Renzo Mazzarotto
Journal:  Front Oncol       Date:  2020-11-27       Impact factor: 6.244
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.